EU and US could reach trade deal this weekend - Reuters
Investing.com - TD Cowen raised its price target on Edwards Lifesciences (NYSE:EW) to $84.00 from $75.00 while maintaining a Hold rating on the stock. The medical device maker, with a market capitalization of $47 billion, is currently trading near its 52-week high of $83.
The price target increase follows Edwards Lifesciences’ strong second-quarter performance, which included both top-line and bottom-line beats, along with positive revisions to its full-year guidance. The company maintains robust fundamentals with a 78.9% gross profit margin and 9.5% revenue growth over the last twelve months. InvestingPro analysis indicates the stock is currently trading above its Fair Value.
According to TD Cowen, the company’s Transcatheter Aortic Valve Replacement (TAVR) unit achieved 7.8% growth at constant currency, with comparable contributions from both U.S. and international markets.
Edwards Lifesciences appears to have maintained its global market share position in the TAVR segment, based on these balanced regional contributions.
TD Cowen’s new price target of $84 represents a multiple of 30 times the firm’s estimated 2026 earnings per share for Edwards Lifesciences.
In other recent news, Edwards Lifesciences reported robust financial results for the second quarter of 2025. The company’s earnings per share (EPS) reached $0.67, surpassing analyst forecasts of $0.62. Revenue also exceeded expectations, coming in at $1.53 billion compared to the anticipated $1.49 billion. This marks the first time in over a year that Edwards Lifesciences achieved double-digit revenue growth. Following these results, RBC Capital raised its price target for the company to $89.00 from $85.00, maintaining an Outperform rating. These developments reflect a positive growth outlook for Edwards Lifesciences, according to RBC Capital. Despite the strong earnings report, the company’s stock saw a decline in value. These recent developments highlight the ongoing interest and analysis surrounding Edwards Lifesciences in the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.